慢性乙型肝炎患者与肝癌患者血清可溶性Fas水平研究

目的 :了解可溶性Fas(sFas)在肝癌细胞及慢性肝炎中的作用。方法 :采用双抗体夹心ELISA法对 18例慢性乙型肝炎 (CH)患者、12例肝癌患者 (HCC)和 6例正常对照者 (NC)血清sFas进行检测 ,并对CH患者血清sFas水平与肝细胞损害程度进行相关性分析。结果 :HCC患者血清sFas水平比CH患者及NC组明显升高 (均P <0 .0 1) ;CH患者血清sFas水平与NC组比较差异有显著性 (P <0 .0 1)。CH患者血清sFas水平与血清ALT/AST ,ALB ,PTA呈负相关 (P <0 .0 1) ,与血清总胆红素呈正相关(P <0 .0 1)。结论 :sFas可阻止肝癌细胞凋亡的发生 ,而慢性乙型肝炎患者sFas与肝脏重症程度具有相关性。

A Comparative study of serum sFas in patients with hepatocellular cancer and chronic hepatitis

Objective To study the effects of sFas in hepatocellular cancer (HCC) and chronic hepatitis (CH). Methods The serum sFas was detected in 18 patients with HCC, 12 patients with CH and 6 cases of normal control by ELISA. Results The serum sFas in HCC was obviously increased and had significant difference with the patients of CH and normal control (P<0.01). The serum sFas had positive correlation with the serum TBIL(P<0.01), but negative correlation with the ALB, PTA and the ratio of ALT/AST(P<0.01).Conclusions sFas may resist the occurrence of HCC apoptosis. In CH, sFas has correlation with the severity of CH. The role of sFas in viral hepatitis is uncertain.